Shire Acquires Foresight Biotherapeutics for $300M

Shire acquires the rights to FST-100, a therapy in late-stage development for the treatment of infectious conjunctivitis, a/k/a pink eye
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news